Time-kill kinetics of anti-tuberculosis drugs, and emergence of resistance, in relation to metabolic activity of Mycobacterium tuberculosis

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 12, 2010, Pages 2582-2589

  de Steenwinkel, Jurriaan E M ^a   de Knegt, Gerjo J ^a   ten Kate, Marian T ^a   van Belkum, Alex ^a   Verbrugh, Henri A ^a   Kremer, Kristin ^b   van Soolingen, Dick ^b   Bakker Woudenberg, Irma A J M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

Amikacin; Antimicrobial activity; Ethambutol; Isoniazid; Mutant selection window; Rifampicin; TB

Indexed keywords

A 3650; AMIKACIN; E 4630; ETHAMBUTOL; I 3377; ISONIAZID; R 3501; RIFAMPICIN; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL CELL; BACTERIAL GROWTH; BACTERIAL METABOLISM; BACTERICIDAL ACTIVITY; BACTERIUM CULTURE; CONTROLLED STUDY; IN VITRO STUDY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN;

ANTITUBERCULAR AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, BACTERIAL; HUMANS; KINETICS; MICROBIAL SENSITIVITY TESTS; MUTATION; MYCOBACTERIUM TUBERCULOSIS; TIME FACTORS;

EID: 78149474564     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq374     Document Type: Article

References (23)

1. WHO. World Health Organization: Global Tuberculosis Control 2009; Epidemiology, Strategy and Financing. WHO Library Cataloguing-inPublication Data. 2009; 1-314.
2. Wright A, Zignol M, Van Deun A et al. Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Lancet 2009; 373: 1861-73.
3. Ginsberg AM. Emerging drugs for active tuberculosis. Semin Respir Crit Care Med 2008; 29: 552-9.
4. Davies GR, Nuermberger EL. Pharmacokinetics and pharmacodynamics in the development of anti-tuberculosis drugs. Tuberculosis (Edinb) 2008; 88 Suppl 1: S65-74.
5. Zhao X, Drlica K. A unified anti-mutant dosing strategy. J Antimicrob Chemother 2008; 62: 434-6.
6. Drlica K, Zhao X. Mutant selection window hypothesis updated. Clin Infect Dis 2007; 44: 681-8.
7. Gumbo T, Louie A, Liu W et al. Isoniazid's bactericidal activity ceases because of the emergence of resistance, not depletion of Mycobacterium tuberculosis in the log phase of growth. J Infect Dis 2007; 195: 194-201.
8. Viveiros M, Portugal I, Bettencourt R et al. Isoniazid-induced transient high-level resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2002; 46: 2804-10.
9. Louw GE, Warren RM, Gey van Pittius NC et al. A balancing act: efflux/influx in mycobacterial drug resistance. Antimicrob Agents Chemother 2009; 53: 3181-9.
10. National Committee for Clinical Laboratory Standards. Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes: Approved Standard M24-A. NCCLS, Wayne, PA, USA, 2003.
11. Lundin A. Use of firefly luciferase in ATP-related assays of biomass, enzymes, and metabolites. Methods Enzymol 2000; 305: 346-70.
12. Prioli RP, Tanna A, Brown IN. Rapid methods for counting mycobacteria-comparison of methods for extraction of mycobacterial adenosine triphosphate (ATP) determined by firefly luciferase assay. Tubercle 1985; 66: 99-108.
13. Hillemann D, Rusch-Gerdes S, Richter E. Evaluation of the GenoType MTBDRplus assay for rifampin and isoniazid susceptibility testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol 2007; 45: 2635-40.
14. Hillemann D, Rusch-Gerdes S, Richter E. Feasibility of the GenoType MTBDRsl assay for fluoroquinolone, amikacin-capreomycin, and ethambutol resistance testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol 2009; 47: 1767-72.
15. Bergval IL, Schuitema AR, Klatser PR et al. Resistant mutants of Mycobacterium tuberculosis selected in vitro do not reflect the in vivo mechanism of isoniazid resistance. J Antimicrob Chemother 2009; 64: 515-23.
16. Mitchison DA, Coates AR. Predictive in vitro models of the sterilizing activity of anti-tuberculosis drugs. Curr Pharm Des 2004; 10: 3285-95.
17. Donald PR, Diacon AH. The early bactericidal activity of anti-tuberculosis drugs: a literature review. Tuberculosis (Edinb) 2008; 88 Suppl 1: S75-83.
18. Colangeli R, Helb D, Sridharan S et al. The Mycobacterium tuberculosis iniA gene is essential for activity of an efflux pump that confers drug tolerance to both isoniazid and ethambutol. Mol Microbiol 2005; 55: 1829-40.
19. Amaral L, Boeree MJ, Gillespie SH et al. Thioridazine cures extensively drug-resistant tuberculosis (XDR-TB) and the need for global trials is now! Int J Antimicrob Agents 2010; 35: 524-6.
20. Herbert D, Paramasivan CN, Venkatesan P et al. Bactericidal action of ofloxacin, sulbactam-ampicillin, rifampin, and isoniazid on logarithmicand stationary-phase cultures of Mycobacterium tuberculosis. Antimicrob Agents Chemother 1996; 40: 2296-9.
21. Mitchison DA. Antimicrobial therapy of tuberculosis: justification for currently recommended treatment regimens. Semin Respir Crit Care Med 2004; 25: 307-15.
22. Mitchison DA. Role of individual drugs in the chemotherapy of tuberculosis. Int J Tuberc Lung Dis 2000; 4: 796-806.
23. Rastogi N, Labrousse V, Goh KS. In vitro activities of fourteen antimicrobial agents against drug susceptible and resistant clinical isolates of Mycobacterium tuberculosis and comparative intracellular activities against the virulent H37Rv strain in human macrophages. Curr Microbiol 1996; 33: 167-75.